ADAMTS7 and atherosclerosis: Overall, strong evidence suggests ADAMTS7 as a promising pharmacological target to treat diseases in which atherosclerosis and vascular smooth muscle cells play a central role.13–15 The inhibition of ADAMTS7, achieved by using compounds able to chelate the catalytic zinc ion, represents a promising novel approach for CHD and atherosclerosis treatment.